Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis
Launched by MEDICAL UNIVERSITY OF GRAZ · Dec 5, 2022
Trial Information
Current as of January 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a treatment called isolated ultrafiltration in patients with end-stage kidney disease who are undergoing hemodialysis. Hemodialysis helps filter waste from the blood, but some patients experience a drop in blood pressure during the treatment, which can lead to serious health issues. The goal of this study is to see if isolated ultrafiltration can help manage these blood pressure drops and improve overall health outcomes for patients.
To participate in the trial, you need to be at least 18 years old and currently receiving hemodialysis for end-stage kidney disease. It's important that you have been stable in your treatment for at least a month and have had significant weight gain between dialysis sessions. Participants will be closely monitored during the trial, and you’ll receive detailed information about what to expect. If you're interested in joining or learning more, please talk to your healthcare provider to see if you might qualify.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Written consent of the participant after being informed
- • At least 18 years of age
- • End stage kidney disease patient undergoing hemodialysis
- • Dry weight stable for a minimum of one month
- • Interdialytic weight gain of \>2 liters in the short interdialytic interval
- Exclusion Criteria:
- • No informed consent was obtained
- • Patients with a pacemaker or implanted medical device that prevents compliance with study regulations
- • Patients treated with hemodiafiltration
- • Patients treated with medium cut-off membranes (Theranova, Baxter)
- • Patients with recurrent severe hyperkalemia after the short interdialytic interval (K+ concentration \> 6.0 mmol/L, requiring more than 2 hours of dialysis to ameliorate the post-dialytic shift from other compartments.
- • Women of childbearing age not using contraception
About Medical University Of Graz
The Medical University of Graz, a leading institution in Austria, is dedicated to advancing medical knowledge and improving patient care through innovative research and clinical trials. Renowned for its interdisciplinary approach, the university collaborates with various healthcare professionals and researchers to explore cutting-edge therapies and treatments. With a commitment to ethical standards and patient safety, the Medical University of Graz actively contributes to the global medical community by facilitating rigorous clinical trials that aim to translate scientific discoveries into practical applications for improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Graz, , Austria
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials